

USSN 09/884,319
Graham *et al.*

REMARKS

Upon entry of the amendment, claims 17 and 26-38 will be pending in the application. Claims 1-16 and 18-25 are canceled. Claim 17 has been amended and claims 26-38 are newly added. Support for the amendment and new claims appears in the specification at, *e.g.*, page 5, lines 3-12 (disclosing that SEQ ID NOS:2, 4, 6, and 7 are IL-1-R intracellular ligand proteins); page 15, lines 3-27 (disclosing that binding inhibitors of IL-1-R intracellular ligand proteins can be used in pharmaceutical compositions, and that these compositions may be accompanied by a pharmaceutically acceptable carrier); page 18, lines 23-32 (disclosing obtaining the antibodies using an IL-1-R intracellular ligand protein as an immunogen, using the immunogen with a cysteine residue at the carboxyl terminus, and the conjugation of the immunogen to a hapten like keyhole limpet hemocyanin); page 19, lines 1-16 (disclosing the use of antibodies as diagnostic agents, neutralizing antibodies, use of antibodies as therapeutics, and the use of antibodies to block binding of IL-1-R to IL-1-R intracellular ligand); and page 27, lines 25-29 (disclosing methods of making monoclonal and polyclonal antibodies). No new matter has been added.

The title and abstract have been amended.


USSN 09/884,319
Graham et al.

CONCLUSION

The application is believed in condition for allowance, and such action is respectfully requested. The Commissioner is authorized to charge any fees that may be due, or credit any overpayments of same, to Deposit Account No. 50-0311, Ref. No. 22058-568 DIV1A CON.

Respectfully submitted,

Dated: July 24, 2003


David E. Johnson, Reg. No. 41,874
Attorney for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

TRA 1814411v3